25 results about "Hippocampal region" patented technology

The application discloses a new use of Leonurine or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating radiation-induced brain injury, specifically, providing a safe and effective therapeutic drug for iron death, neuroinflammation, neuron damage and lipid metabolism disorder accompanying the radiation-induced brain injury, solving the technical problem of lack of specific treatment means in the prior art, and having a wide clinical application prospect. Experiments adopt a C57BL / c mouse 30 Gy whole brain X-ray radiation model, and results show that Leonurine can significantly improve the body weight decrease and survival rate of the model mice, reduce the serum IL-6 and IFN-alpha levels, inhibit the activation of microglial cells in the cerebral cortex and hippocampus, protect and repair damaged neurons, and improve the ultrastructure of mitochondria and synapses; meanwhile, the expression of GPX4 and SLC7A11 proteins in the brain tissue is up-regulated, the GSH content is increased to inhibit iron death, and the levels of GPE, GPS and GPC related to lipid metabolism are restored.

The invention discloses armillariella mycelium polysaccharide ATMP capable of improving cognitive impairment and a preparation method and application of the armillariella mycelium polysaccharide ATMP. The polysaccharide is composed of two components, and the molecular weights of the two components are 2.30 * 10 < 4 > Da and 4.56 * 10 < 5 > Da respectively; the monosaccharide composition comprises mannose (Man), glucose (Glc) and galactose (Gal), and the molar ratio of the mannose (Man) to the glucose (Glc) to the galactose (Gal) is 1: 16.64: 1.96. Animal experiment results show that the armillariella mycelium polysaccharide ATMP can improve cognitive impairment induced by lipopolysaccharide (LPS) by improving the spatial memory ability of mice, repairing the disorder state and deletion injury of neurons in a hippocampal region and relieving neuroinflammatory response, so that the obvious neuroprotective effect is achieved. As a natural brain-benefiting active component, the armillariella tabescens mycelium polysaccharide ATMP has a wide application prospect in the related fields of brain health.

The application discloses an application of Campanula medium in treatment of perimenopausal depression, and a method is as follows: Campanula medium is added into 10 times of distilled water in weight, decocted for 1 h and filtered, residues are added with 8 times of distilled water, and then decocted for 1 h and filtered, and filtrates are combined, and concentrated into 1 g / mL of medicinal liquid according to medicinal material, so that Campanula medium medicinal liquid is obtained. According to the experimental result, Campanula medium can improve the depression and anxiety behavior of PMD model mice. Campanula medium can improve the hippocampus tissue morphology and structure of the PMD model mice, increase the neuron Nissl body abundance of the hippocampus, promote the ER-BDNF-TrkB path, improve the monoamine neurotransmitter level, correct the HPA axis hyperactivity, and thus improve the depression behavior.

The present invention provides a basis for using soluble fiber, particularly compositions comprising Agave fructans, to prevent or treat the accumulation of lipids, particularly ceramides in the liver and brain and lipofuscin in the liver, improving the overall integrity of both organs, with treatment being feasible to prevent fatty liver disease and also prevent Alzheimer's disease (AD). In the present invention, we analyze alterations in lipid metabolism in the liver and ceramide production in the brain of transgenic mice (APP / PS1, TG) for AD. Our results indicate that microvesicular lipid accumulation within hepatocytes is increased in TG mice compared to the control group. Furthermore, in the brains of TG mice, a greater accumulation of ceramides is observed in the somatosensory cortex and entorhinal cortex; in the CA1 region of the hippocampus and in the motor cortex, no significant increase was observed when compared to the control group.

The invention discloses a composite microneedle with bacterial outer membrane vesicles loaded with active ingredients as well as a preparation method and application of the composite microneedle. The composite microneedle is prepared from the bacterial outer membrane vesicles and the active ingredients loaded in the bacterial outer membrane vesicles, the bacterial outer membrane vesicles are derived from mucus eubacterium, the active ingredient is cycloastragenol, and the composite microneedle has a transdermal delivery function and delivers the active ingredient to a target tissue in a targeted manner. The method comprises the following steps: firstly, encapsulating cycloastragenol into mucus eubacterium outer membrane vesicles through a co-incubation or active drug loading technology to form a composite nano-carrier; the EL-OMVs-CAG compound prepared by the invention has good biocompatibility and blood brain barrier penetrating ability, and can target a central nervous system, regulate the activity of microglial cells, inhibit neuroinflammatory response and reduce synaptic loss and neuronal apoptosis in a hippocampal region, so that cognitive function impairment caused by operation and anesthesia is improved.

The present invention relates to uses of regulatory T cells manipulated to overexpress CX3CR1. The regulatory T cells induced to overexpress CX3CR1 according to the present invention reduce microglial activation in an LPS-induced neuroinflammation animal model and suppress immune inflammatory responses of activated microglia by inhibiting the expression of pro-inflammatory markers and cytokines in the cortical and hippocampal regions of the brain, and thus can be used for reducing microglial activation or for treating neuroinflammatory diseases or neurodegenerative diseases caused by hyperactivation of microglia in the brain.

The application provides a robot positioning mapping method based on a visual cortex and hippocampus space coding, and the method comprises the following steps: acquiring linear velocity and angular velocity through a wheel encoder and an inertial measurement unit, and obtaining robot pose information through path integration; collecting scene images by using a camera and extracting GIST features, obtaining a winning cell in a view cell network through Euclidean distance matching, updating weights, and introducing a posteriori entropy adaptive threshold to perform robust scene matching; storing the pose information and the successfully matched weight vector into a hippocampus CA1 area location cell, eliminating cumulative errors through iterative optimization, controlling the map size through space density redundancy pruning, and adopting a hierarchical switching strategy to perform scale stretching optimization, so that fast mapping is realized. Through simulating a biological space coding mechanism, the application improves scene recognition robustness, positioning consistency and mapping efficiency, and is suitable for intelligent navigation of a mobile robot.

The present disclosure relates to the field of biomedicine, and discloses a nutritional composition for intervention or treatment of autism and a preparation method thereof, aiming to solve the problems of safety, compliance and insufficient targeting mechanism of existing intervention programs for social impairment of autism. The composition comprises leucine, isoleucine and valine in a molar ratio of 1:1:1, with a total concentration of 0.753 mg / kg of body weight, in the form of oral liquid, and a pH of 6.87.4. The preparation method comprises weighing the amino acids according to the molar ratio, dissolving them in 0.9% sodium chloride injection, filtering, dispensing and sealing. The present application can safely and effectively improve the social impairment of autism patients and plays a role by up-regulating the expression of MyT1L in the hippocampus.

The present application relates to a pharmaceutical composition for treating chronic pain and pain-related memory impairment diseases, and belongs to the technical field of biological medicine. Through animal experiments, it is confirmed that the expression of C3 in the hippocampal area of chronic pain mice is increased, and exogenous C3 injection can induce pain and memory impairment phenotype. The present application proposes to use C3-C3aR inhibitors, such as small molecule inhibitor SB290157, to block the pathway. The pharmaceutical composition can be administered by systemic injection or targeted brain region administration to achieve intervention. C3aR inhibitors can simultaneously improve pain behavior and memory function in SNI model mice. By regulating the C3-C3aR signaling pathway in the hippocampal area, the present application directly acts on the pathological core link of pain-memory comorbidity, and provides a small molecule targeted treatment path for chronic pain patients.

The invention discloses an application of polypeptide in preparation of antidepressant drugs, and belongs to the field of biological medicine, the polypeptide is neuropeptide PEN or a functional fragment and a derivative thereof, and the PEN is one of a plurality of derivative peptides formed by cutting a protein precursor proSAAS existing in a central nervous system of a mammal through proprotein convertase. Research finds that PEN as an endogenous polypeptide can significantly shorten the immobility time of a mouse in a tail suspension experiment and a forced swimming experiment and improve the depression-like behavior of the mouse, shows an obvious anti-depression effect, and has no obvious influence on the movement function of the mouse. A further research result shows that the anti-depression mechanism of PEN is related to inhibition of NMDAR2B / CaMKII signals of a mouse hippocampus and increase of ERK1 / 2 protein activity of the hippocampus. The invention discovers potential application of PEN in preparation of antidepressant drugs for the first time, and provides a new target and theoretical basis for development of novel, safe and effective antidepressant drugs.

The application relates to a system and method for treating Alzheimer's disease, and belongs to the field of medical devices. The system comprises a multi-modal data acquisition module, an individualized simulation navigation module, a precise signal generation and driving module, and a closed-loop feedback control module. The system constructs an individual head model through finite element analysis to optimize electrode distribution, generates an interference envelope in the hippocampus area by using two high-frequency currents, and realizes closed-loop adjustment of parameters by combining a repeated continuous mode and physiological feedback. The application realizes non-invasive and accurate regulation of a deep target point, significantly improves hippocampal oscillation synchronization and synaptic plasticity, improves the memory of patients, reduces the activation of the surface cortex, and has good clinical safety.

The application discloses an olfactory training system for activating a motor-olfactory-hippocampal neural network and application, the system comprises a plurality of different odor sources, the odor source is used for alternating olfactory stimulation to stroke patients, so as to improve the cognitive function and / or olfactory function of the patient. The application firstly discloses that the function connection of the motor-olfactory-cognitive brain area is disordered after stroke, the function of the VIP neuron of the motor cortex (MO) around the infarction is inhibited; the VIP neuron of the MO region dominates the GABA neuron of the dorsal peripeduncular area (DP) through an inhibitory pathway, activating the pathway can remove the inhibition of the glutamatergic pyramidal neuron of the DP, enhance the excitatory input to the hippocampal CA3 region, and restore the olfaction and spatial memory. The application proves that the structured olfactory training can activate the loop, and significantly improve the cognitive function of the stroke patient. The application provides a simple and non-invasive stroke rehabilitation strategy.

This invention discloses an implantable medical device comprising a polyethylene glycol diacrylate hydrogel matrix and monodisperse guanine peptide nucleic acid self-assembled microspheres immobilized within the polyethylene glycol diacrylate hydrogel matrix. The guanine peptide nucleic acid self-assembled microspheres exhibit a spatial quasi-periodic distribution within the hydrogel matrix characterized by short-range order and long-range disorder. This implantable medical device combines the light-harvesting advantages of biomimetic structures, the wide bandgap photoelectric properties of bio-organic semiconductors, and the flexible tissue integration capabilities of hydrogels to obtain an amorphous photonic crystal material with programmable optical properties and wide bandgap semiconductor properties. This product aims to achieve efficient, stable, and biosafe neurophotomodulation and, through mechanisms such as enhancing cortical gamma oscillations, effectively activating disease-related microglia in the hippocampus, and promoting the clearance of β-amyloid plaques, provides a novel, non-genetic, implantable optical therapy strategy for neurodegenerative diseases.

The invention discloses a method for researching a mild cognitive impairment action mechanism of a cornu cervi pantotrichum polypeptide based on a Wnt / beta-catenin signal channel, relates to the technical field of mechanism analysis, and solves the problem of difficulty in realizing spanning from basic research to clinical transformation in the prior art. Randomly dividing the rats into five groups of blank control, model, positive control and VAP high / low dose, continuously performing intragastric administration on each group for 18 days, and feeding distilled water into the blank and model groups; 2 mg / kg scopolamine is injected into abdominal cavities of the model group after 18 days and 2 hours, and normal saline is injected into the blank group; the scopolamine model is used for measuring the 2min static / motion time of the rat by using an open field experiment, and the unilateral common carotid artery ligation model is used for measuring the escape latency / platform penetration times by using a water maze; the method comprises the following steps: taking blood, separating a hippocampal region, and carrying out HE dyeing, ELISA and Western blot; sPSS 21.0 analysis and single factor variance analysis are used for evaluating the difference and Plt; 0.05 or Plt; 0.01 has statistical significance.

The application provides a circular RNA circ_0004801 and application thereof in Alzheimer's disease treatment; a nucleotide sequence of the circular RNA circ_0004801 is shown as SEQ ID NO:1. Expression of the circular RNA circ_0004801 in hippocampus tissue of AD mice is significantly up-regulated, the circular RNA circ_0004801 acts as a "sponge" of miR-7688-5p, and plays a role by regulating TTBK1 expression and tau phosphorylation level. Knocking down the circular RNA circ_0004801 can obviously improve spatial learning and memory of 3xTg mice, significantly reduce tau protein phosphorylation level in hippocampus and NFTs density in hippocampus DG region. Therefore, the circular RNA circ_0004801 and miR-7688-5p can be used as a new target for treating AD. The application first finds that the circular RNA circ_0004801 regulates TTBK1 through a ceRNA mechanism, thereby driving tau hyperphosphorylation, and provides a new molecular target for early intervention treatment of AD based on circRNA and miRNA.

This invention belongs to the field of medical technology, specifically relating to the preparation of CD73-positive NK cells from umbilical cord blood of different origins and their application in the treatment of Alzheimer's disease. This invention studies CD73-positive NK cells differentiated from different cell types originating from umbilical cord blood (CD34-positive cells, CD3-negative / CD56-positive cells, and CD56-negative cells). + NK cells were found to differentiate into CD73 from all initial cell types derived from umbilical cord blood. + NK cells, and 34 + -73-NK cells showed a higher growth rate, 56 － -73-NK cells exhibited stronger cytotoxicity, and 56 － -73-NK cells showed better overall efficacy than 34- + -73-NK cells. Further research indicates that CD73 + NK cells can inhibit the activation of microglia and astrocytes in the hippocampus of STZ-injected mice, thereby reducing neuroinflammation in the hippocampus and potentially providing a new solution for the treatment of AD.

The invention provides application of an NLRP3 inhibitor in preparation of a medicine for preventing, relieving, improving or treating epilepsy and symptoms of a nervous system associated with the epilepsy. The NLRP3 inhibitor can relieve atrophy of the hippocampus of a subject, improve loss of neurons in the hippocampus of the subject, improve theta rhythm loss in the attack interval of the subject, improve cognitive impairment, improve anxiety and depression behaviors and improve cognitive memory function.

The invention provides a mouse model construction method for simulating the morbidity process of brain premature senility, ABAD knock-down is achieved in the hippocampus of a healthy adult mouse, and the pathological process of brain premature senility morbidity is simulated. According to the mouse model obtained by the invention, the expression quantity of the brain hippocampus ABAD gene is 30% or more lower than that of a wild type mouse, and the mouse model shows pathological characteristics which tend to be consistent with those of a mouse with brain premature senility.

The invention relates to a polypeptide, a derivative of the polypeptide, a conjugate of the polypeptide and new application of the polypeptide. The amino acid sequence of the polypeptide is as shown in SEQ ID No. 1. The polypeptide can reverse the weakening of cell proliferation activity of mouse hippocampal neuron cells HT-22 induced by an A beta1-40 oligomer, and reduce p-Tau protein overexpression and cell axon structure damage in the HT-22 cells caused by the A beta1-40 oligomer; the polypeptide promotes the proliferation and differentiation of the neural stem cell line C17.2 cells treated by the A beta1-40 oligomer; the polypeptide can significantly improve Alzheimer's disease related pathological changes in cerebral cortex and hippocampus of a mouse and promote neurogenesis of the hippocampus, so that related cognitive functions of learning, memory and the like of an Alzheimer's disease model mouse are recovered, and the effect of treating the Alzheimer's disease is achieved; the polypeptide can be used for preparing a low-toxicity, safe and effective Alzheimer's disease therapeutic agent, and a new way is provided for treating Alzheimer's disease.

The invention is applicable to the technical field of biological medicines, and provides application of ginsenoside CK in preparation of a medicine for preventing or treating Alzheimer's disease. Experiments prove that the ginsenoside CK can significantly improve the spatial learning and memory ability of AD model animals and relieve anxiety behaviors of the AD model animals; the deposition of brain tissue hippocampal Abeta (1-42) protein is effectively reduced, and the key molecular pathology of AD is relieved from the source; the level of key inflammatory factors in brain tissues and serum is strongly inhibited, and AD-related chronic neuroinflammation is controlled; according to the present invention, the CK has the specific protection effect on the hippocampal neuron structure, such that the CK can be adopted as the multi-target treatment agent so as to prevent and / or treat the Alzheimer's disease.

The invention belongs to the field of biological medicine, and relates to a potential drug system for gene therapy of Alzheimer's disease (AD), which comprises cDNA of hHEBP1 and a carrier system thereof. The vector system is a recombinant system of plasmid and virus AAV2, and comprises an hCD68 promoter, a CMV enhancer and a WPRE sequence. When AD treatment is carried out, AAV virus particles are assembled after in-vitro culture, and core elements contained in the virus particles sequentially comprise an MV enhancer, an hCD68 promoter, cDNA of hHEBP1 and a WPRE structure. In a preclinical animal experiment, the system can realize long-term stable expression of HEBP1 in microglia cells in a hippocampus region, realizes repair of neuronal cells, and provides a new selection scheme for AD gene therapy.

The invention discloses a lactobacillus rhamnosus HL-JO04 capable of inhibiting helicobacter pylori and improving GABA (gamma-aminobutyric acid) concentration of a nervous system and application of the lactobacillus rhamnosus HL-JO04. The lactobacillus rhamnosus HL-JO04 not only can effectively inhibit growth of the helicobacter pylori, but also can prevent the helicobacter pylori from being adhered to epithelial cells of human gastric mucosa, and has the characteristic of improving GABA concentration of a hippocampus. The strain is high in growth and reproduction rate, high in freeze-dried bacterial powder activity and high in digestive tract tolerance, and is suitable for industrial application. The high-activity lactobacillus rhamnosus capable of inhibiting the growth and colonization of the helicobacter pylori and producing the GABA at high yield is adopted, so that a wider treatment choice is provided for treating helicobacter pylori infection as well as flora imbalance and related mental problems caused by the use of a large dose of antibiotics.

The application provides a traditional Chinese medicine compound essential oil and application thereof in preparation of an antidepressant product, and relates to the technical field of traditional Chinese medicine essential oil pharmaceuticals. The traditional Chinese medicine compound essential oil is composed of benzoin essential oil 3-15 parts, Chinese rose flower essential oil 2-10 parts, immature bitter orange fruit essential oil 2-10 parts, white cardamom essential oil 1-8 parts and fennel essential oil 1-8 parts. The traditional Chinese medicine compound essential oil is administered in the form of sniffing, stimulates olfactory nerves, influences the cerebral cortex margin and neurotransmitters, and realizes improvement of brain depression-like symptoms. After the CUMS depression animal model is treated with the traditional Chinese medicine compound essential oil, the symptoms of loss of pleasure are reversed and improved, the state of reduced movement of the animal is improved, and the behavior state of the depression animal model of despair and giving up struggle is obviously improved. Meanwhile, the levels of DA, 5-HT and NE in the brain tissue of the depression animal model are significantly improved, and the pathological changes in the hippocampus region of the depression animal model are obviously improved. The traditional Chinese medicine compound essential oil can be used for preparing drugs for aromatherapy, has no adverse reactions, has high acceptability, and provides a new way for the treatment of depression.

The application discloses a method for constructing a microwave radiation animal brain injury model based on a medial septum-hippocampus CA3 cholinergic nerve loop regulation, comprising the following steps: setting electromagnetic radiation conditions, and performing electromagnetic radiation treatment on test animals; comparing whether a cholinergic nerve loop between the medial septum and the hippocampus CA3 is activated before and after the electromagnetic radiation treatment; and if the cholinergic nerve loop is activated, constructing an electromagnetic radiation animal brain injury model by using the electromagnetic radiation conditions. The application can accurately construct the electromagnetic radiation animal brain injury model, and increases the possibility of elucidating the molecular mechanism of the electromagnetic radiation brain injury effect and the research and development of prevention and treatment drugs.

This invention discloses a type of Lactobacillus paracasei ( Lactobacillus paracasei Preparation of Lactobacillus paracasei F5 and polysaccharide synbiotic composition and its application in alleviating behavioral cognitive impairment in the elderly. This strain is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 35145, dated July 9, 2025. The synbiotic composition consists of lyophilized Lactobacillus paracasei F5 powder and arabinoxylan (AX) or galactooligosaccharides (GOS) in a specific mass ratio, with a viable count ≥ 1 × 10⁻⁶. 8 CFU / g. In an Aβ transgenic fruit fly model, administration of the synbiotic for 8 consecutive days significantly improved the climbing ability of the model fruit flies and reduced Aβ levels in the brain. 42 Levels of AChE and cyclic adenosine monophosphate (cAMP) were observed. In a mouse model induced by AlCl3 combined with D-gal, continuous gavage for 11 weeks significantly reversed learning and memory deficits and downregulated Aβ levels in the hippocampus. 42 This study aims to reduce the deposition and AChE activity of pro-inflammatory factors in the cerebral cortex, providing a safe and feasible strategy for dietary intervention in cognitive impairment in the elderly, with broad application prospects.